Orphan Drugs & Rare Diseases 2017 Americas

3.3 from 15 votes
Date: 12 - 14 September, 2017
Location: San Francisco, CA, USA

The global orphan drugs market is expected to grow at a steady CAGR of 11.43% from 2016 to 2022. At the current forecasted growth rate, the orphan drugs market is expected to grow from USD 111.87 billion in 2016 and become worth USD 214.14 billion by 2022.

The growth of the global orphan drugs market is increasing due to the growing rare diseases. Orphan diseases are rare in nature which means its occurrence rate is very low, but its prevalence rate is expected to increase in the forecasted period thereby increasing the demand of global orphan diseases market. There are around 7000 rare types of rare diseases and disorders, these numbers are increasing day by day. 80% of rare diseases are genetically originated and rest are result of infections, environmental causes and allergies. Around 50% of genetic diseases are in children's, 30 % of children with rare diseases cannot live for more than 5 years. Rare diseases are one of the life-threatening diseases that kills millions of lives worldwide. Orphan drugs are the pharmaceutical agent that is specially developed for rare diseases. The prevalence rate of rare diseases are growing at a faster rate, the result in growing need of drugs to cure that diseases.

Paradigm Global Events is again proud to present our bi-annual Orphan Drugs & Rare Diseases Global Congress 2017 Americas. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing, access and more. We look forward to having you be part of the event!

The two-day Congress will provide an interactive and intimate discussion and networking format led by key industry speakers with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.

Gain Latest Insights On:

In-depth analysis of the orphan drugs markets
Focus on the existing and future trends
Highlights on the key growth and investments
Insights on key technological trends impacting the orphan drugs market
Understanding the roles of the key players and stakeholders
Learn the key economic drivers in the orphan market
The Roles of Big Pharmas, Biotechs and Start-Ups
What Strategies Are Available to Ensure Partnership Success
Clinical Trials: From Early Drug Development to Patient Recruitment and More
Pricing Strategy: How to Price Correctly?

Who you will meet

Presidents, Heads/Chiefs, Directors, VPs and Managers of:

Research and Development
Regenerative Medicine
External R&D Innovation
Clinical Scientist
Gene Therapy
Translational Science
Molecular Geneticist
Program Management
Patient Advocacy and Public Affairs
Medical Affairs
Regulatory Affairs
Clinical Field Specialist
Sales and Marketing
Outcomes & Evidence
Commercial Development
Product Specialist
Global Strategic Services
Business Planning and Operations

Featuring Key Industry Experts

Omar Khwaja, MD PhD, Global Head of Rare Diseases, F. Hoffmann-La Roche
David Rintell, Head of Global Patient Advocacy, Rare Diseases, Sanofi Genzyme*
Dr. Tim Cote, Principal and CEO, Cote Orphan
Amit K. Sachdev, Executive VP, Chief Regulatory Officer and Chief of Staff to the CEO, Vertex
Paresh N. Soni, MBChB, PhD, FCP (SA), MMed, Chief Medical Officer, Albireo Pharm
Dr. Ken Kengatharan, President & iCEO, Armetheon Inc.
Dr Will Maier, Chief Scientific Officer, MAPI Group
Kelly Franchetti, Vice President Global Patient Insights and Engagement, MAPI Group
Rory Graham, Senior Director EU regulatory Services, MAPI Group
Immo Zadezensky, Senior Director, Head US for Global Regulatory and Scientific Policy, EMD Serono, Inc
Christopher Gibson, Co-Founder and CEO, Recursion Pharmaceuticals
Dr. John P. Cooke, Chair, Department of Cardiovascular Sciences, Houston Methodist Research Institute
Natalie C. Holles, Senior Vice President and Chief Operating Officer, Audentes Therapeutics, Inc.*
Eduardo Bruno Martins, MD, DPhil, Sr. VP, Liver & Infectious Diseases Drug Dev't., Eiger BioPharmaceuticals
Matthias Bödding, Head Global Drug Safety Medicine, Merck
Carlos R. Camozzi, Group Chief Medical Officer (CMO), Simbec Orion
Anja Harmeier, Global Project Leader for Rare Diseases, F. Hoffmann-La Roche Ltd
Samantha Parker, Chief Patient Affairs/Health Policies Officer, LYSOGENE
Sandra Shpilberg, CEO, Seeker Health
Shinichi Torii, VP, Head of R&D, Biogen Idec Japan*
Michael Harbour, MD, FACP, Global Exec. Director Infectious Diseases, Office of the Chief Medical Officer, Merck*
Alastair MacDonald, Executive Director Real World & Late Phase, INC Research
Jason Cameron, Vice President, Global Supply Chain, Amicus Therapeutics UK Limited
Jas Khera, Managing Director, WEP Clinical
Amandip Sidhu, Senior EAP Director, WEP Clinical


3.3 from 15 votes